AbbVie Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 1 sell rating, 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AbbVie stock.
View analyst ratings for AbbVie or view top-rated stocks.

Wall Street analysts have given AbbVie a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AbbVie wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for AbbVie.

AbbVie Inc. (NYSE:ABBV) issued its earnings results on Thursday, April, 29th. The company reported $2.95 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.83 by $0.12. The company had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.84 billion. AbbVie had a trailing twelve-month return on equity of 136.75% and a net margin of 10.28%. The company's revenue for the quarter was up 50.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.42 earnings per share.
View AbbVie's earnings history.

AbbVie's stock was trading at $84.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABBV shares have increased by 33.3% and is now trading at $113.12.
View which stocks have been most impacted by COVID-19.

AbbVie declared a quarterly dividend on Thursday, June 17th. Shareholders of record on Thursday, July 15th will be given a dividend of $1.30 per share on Monday, August 16th. This represents a $5.20 annualized dividend and a yield of 4.60%.
View AbbVie's dividend history.

AbbVie pays an annual dividend of $5.20 per share and currently has a dividend yield of 4.53%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. AbbVie has been increasing its dividend for 49 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AbbVie is 49.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AbbVie will have a dividend payout ratio of 37.14% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
View AbbVie's dividend history.

AbbVie issued an update on its FY 2021 earnings guidance on Friday, May, 7th. The company provided earnings per share (EPS) guidance of 12.370-12.570 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $12.450. The company issued revenue guidance of $55.90 billion-$55.90 billion, compared to the consensus revenue estimate of $55.34 billion.

13 Wall Street analysts have issued twelve-month price objectives for AbbVie's shares. Their forecasts range from $98.00 to $144.00. On average, they anticipate AbbVie's share price to reach $120.33 in the next year. This suggests a possible upside of 6.4% from the stock's current price.
View analysts' price targets for AbbVie or view top-rated stocks among Wall Street analysts.

580 employees have rated AbbVie CEO Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among AbbVie's employees.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of ABBV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.17%), Price T Rowe Associates Inc. MD (1.82%), Geode Capital Management LLC (1.54%), Northern Trust Corp (1.34%), Berkshire Hathaway Inc (1.29%) and Bank of New York Mellon Corp (1.17%). Company insiders that own AbbVie stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase.
View institutional ownership trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Berkshire Hathaway Inc, Assenagon Asset Management S.A., Menora Mivtachim Holdings LTD., Lazard Asset Management LLC, Fred Alger Management LLC, APG Asset Management N.V., and Jupiter Asset Management Ltd.. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Carrie C Strom, Elaine K Sorg, Jeffrey Ryan Stewart, Richard A Gonzalez, and Timothy J Richmond.
View insider buying and selling activity for AbbVie or view top insider-selling stocks.

ABBV stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Morgan Stanley, Canada Pension Plan Investment Board, BlackRock Inc., Diamond Hill Capital Management Inc., Capital International Investors, Clarus Group Inc., and Panagora Asset Management Inc.. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase.
View insider buying and selling activity for AbbVie or or view top insider-buying stocks.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABBV stock can currently be purchased for approximately $113.12.

AbbVie has a market capitalization of $199.80 billion and generates $45.80 billion in revenue each year. The company earns $4.62 billion in net income (profit) each year or $10.56 on an earnings per share basis.

AbbVie employs 47,000 workers across the globe.

The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.

AbbVie was founded in 2013.

The official website for AbbVie is www.abbvie.com.

AbbVie is headquartered at 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.